This interim order delivered by the High Court of Jammu & Kashmir and Ladakh at Srinagar addresses a Public Interest Litigation (PIL) filed by the Hemophilia Society of Kashmir concerning critical medical deficiencies. During the proceedings, the petitioner brought to the notice of the Court an acute shortage of vital life-saving drugs, namely “Factor-VIII” and “Emicizumab”, required for hemophilia patients. Expressing grave concern over patient welfare, the High Court issued immediate directions to the Principal of Government Medical College (GMC), Srinagar, and the J&K Medical Supplies Corporation Limited to ensure the urgent procurement and supply of these medicines without any avoidable delay.
- Factual Matrix: An additional affidavit was filed pursuant to the Court’s earlier order dated April 8, 2026, during the ongoing hearing of the PIL instituted by the Hemophilia Society of Kashmir.
- Identification of Critical Shortage: The petitioner’s counsel highlighted an urgent and acute scarcity of essential anti-hemophilic medicines, specifically “Factor-VIII” and “Emicizumab”, threatening the lives and well-being of patients.
- Directives to Medical Authorities: The Principal of Government Medical College, Srinagar, was explicitly directed to immediately address the deficiency so that no patient suffers due to the unavailability of these life-saving drugs.
- Procurement and Supply Mandate: The Court ordered that if any requisition for Factor-VIII and Emicizumab is raised, the J&K Medical Supplies Corporation Limited or any other responsible procurement authority must respond and fulfill it immediately without delay.
Compliance and Next Hearing: The Principal of GMC, Srinagar, was directed to file an affidavit outlining the steps taken within two weeks, and the matter was listed for further hearing on August 10, 2026.
J.O. (Web) 2026 J & K 19
Hemophilia Society of Kashmir Through Its President v. Union Territory of J&K and Ors. (D.O.J. 13.07.2026)
J.O. (Web) 2026 J & K 19 click here to view full text of judgment




